- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01940913
Efficacy and Safety of a Probiotic Product in Children With Antibiotic-associated Gastrointestinal Disorders.
May 8, 2014 updated by: Probi AB
To assess the tolerability and effect of a probiotic product, when co-administered with antibiotics, on the incidence and duration of loose/watery stools following the antibiotic treatment in children.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
400
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Warsaw, Poland
- Multicenter study at 13 health care centers in Warsaw
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 11 years (Child)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Description
Inclusion criteria
- Children at the age of 1-11 years that have been ordinated to start antibiotic treatment except for penicillin.
- Possibility to initiate the probiotic treatment within 24 hours after the first dose of the antibiotic treatment.
- Children whose parents or legal caregivers have signed the informed consent to participate in the study.
Exclusion criteria
- Chronic intestinal disease.
- Current immunodeficiency or immunosuppressive treatment.
- Chronic or acute diarrhoeal disease.
- Use of laxatives the week before inclusion in the study.
- Antibiotic treatment for the last four weeks before inclusion in the study.
- Known hypersensitivity to any of the ingredients in the probiotic product or the placebo [potato starch, silicon dioxide, capsule (hypromellose, water) ± bacterial culture].
- Intake of any probiotic products for the last two weeks before inclusion in the study.
- Patient requiring hospitalisation. Lack of parents´/legal guardians´ informed consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
|
|
Active Comparator: Probiotics
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Reduction of the incidence of loose/watery stools following antibiotic treatment in children.
Time Frame: 19-24 days
|
19-24 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2013
Primary Completion (Actual)
April 1, 2014
Study Completion (Actual)
May 1, 2014
Study Registration Dates
First Submitted
September 9, 2013
First Submitted That Met QC Criteria
September 9, 2013
First Posted (Estimate)
September 12, 2013
Study Record Updates
Last Update Posted (Estimate)
May 9, 2014
Last Update Submitted That Met QC Criteria
May 8, 2014
Last Verified
May 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ProAAD
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Antibiotic-associated Loose/Watery Stools
-
Liaquat University of Medical & Health SciencesUniversity of Urbino "Carlo Bo"Not yet recruiting
-
University Hospital, GenevaBioMérieux; Hospital Fribourg, Switzerland; Centre Hospitalier du Centre du Valais and other collaboratorsNot yet recruitingAntibiotic Stewardship | Antibiotic | VAP - Ventilator Associated Pneumonia | Intensive Care (ICU) | Antibiotic Prescribing for Acute Respiratory-tract InfectionsSwitzerland
-
Seed HealthCompletedMetagenomic and Metabolomic Reconstitution of Gut Microbiota After Broad Spectrum Antibiotic TherapyAntibiotic-associated Diarrhea | Antibiotic Side Effect | Antibiotic-induced Dysbiosis | Antibiotic-induced Epithelial Barrier DisintegrityCanada
-
Genzyme, a Sanofi CompanyCompletedClostridium Difficile-Associated Diarrhea | Antibiotic-associated Diarrhea | Clostridium Enterocolitis | Clostridium Difficile Diarrhea | Antibiotic-associated ColitisUnited States, Canada, United Kingdom, Puerto Rico
-
South Shore HospitalWithdrawnAntibiotic Associated Diarrhea | Clostridium Difficile Associated Diarrhea
-
Georgetown UniversityUniversity of Maryland, Baltimore; National Center for Complementary and Integrative... and other collaboratorsCompletedAntibiotic-associated DiarrheaUnited States
-
Neopharm Bulgaria Ltd.CompletedEfficacy and Safety of Sinquanon for Prevention of Antibiotic-associated Diarrhea in Adults (SPAADA)Antibiotic-associated DiarrheaBulgaria
-
SandozCompletedAntibiotic-associated DiarrheaRussian Federation
-
Medical University of WarsawWinclove Probiotics B.V.CompletedAntibiotic-associated DiarrheaPoland, Netherlands
-
Eskisehir Osmangazi UniversityHacettepe University; Yuzuncu Yıl University; Goztepe Training and Research Hospital and other collaboratorsCompletedAntibiotic Associated DiarrheaTurkey
Clinical Trials on Placebo capsules
-
TenNor Therapeutics (Suzhou) LimitedThe First Hospital of Jilin UniversityCompletedHelicobacter Pylori InfectionChina
-
AfimmuneTerminatedType 2 Diabetes | HypertriglyceridemiaGeorgia, United States, Germany, Israel, Latvia, Switzerland
-
Chinese Academy of Medical Sciences, Fuwai HospitalNot yet recruiting
-
AbbottQuintiles, Inc.Terminated
-
Guang'anmen Hospital of China Academy of Chinese...Beijing Anzhen HospitalCompleted
-
Yilai ShuHangzhou PhecdaMed Co., Ltd.Not yet recruitingDeafness | Age Related Hearing LossChina
-
Chinese Academy of Medical Sciences, Fuwai HospitalNational Natural Science Foundation of ChinaRecruiting
-
Caelus Pharmaceuticals BVCompleted
-
Massachusetts General HospitalCompleted
-
BiogenTerminatedConnective Tissue Disease-Associated Pulmonary Arterial HypertensionUnited States, Spain, Japan, Australia, United Kingdom, Canada, Germany, Belgium, Argentina, Israel, Mexico, Brazil, Czechia, Netherlands, Philippines